CoChat

The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.

Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment

Reynolds, Gavin P, McGowan, Olga O · 2017 · Journal of Psychopharmacology

Abstract

The increase in cardiovascular disease and reduced life expectancy in schizophrenia likely relate to an increased prevalence of metabolic disturbances. Such metabolic risk factors in schizophrenia may result from both symptom-related effects and aetiological factors. However, a major contributory factor is that of treatment with antipsychotic drugs. These drugs differ in effects on body weight; the underlying mechanisms are not fully understood and may vary between drugs, but may include actions at receptors associated with the hypothalamic control of food intake. Evidence supports 5-hydroxytryptamine receptor 2C and dopamine D2 receptor antagonism as well as antagonism at histamine H1 and muscarinic M3 receptors. These M3 receptors may also mediate the effects of some drugs on glucose regulation. Several antipsychotics showing little propensity for weight gain, such as aripiprazole, have protective pharmacological mechanisms, rather than just the absence of a hyperphagic effect. In addition to drug differences, there is large individual variation in antipsychotic drug-induced weight gain. This pharmacogenetic association reflects genetic variation in several drug targets, including the 5-hydroxytryptamine receptor 2C, as well as genes involved in obesity and metabolic disturbances. Thus predictive genetic testing for drug-induced weight gain would represents a first step towards personalised medicine addressing this severe and problematic iatrogenic disease.

Overview

Integrity signals

Registry

Crossref · 10.1177/0269881117722987

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 77 references

Research works printed but not linked: 2

  1. 10.1037/0735-7044.105.2.272 · DOI
  2. Reynolds GP, 2016, Poster presented at British Association for Psychopharmacology Summer Meeting

Cited by

See all 69

Metadata

Authors
Reynolds, G. P., & McGowan, O. O.
Affiliations
  • Sheffield Hallam University (GB)
  • NHS Lanarkshire (GB)
Corresponding author
Reynolds, Gavin P
Venue
Journal of Psychopharmacology
Published
2017-09-11
Volume
31
Issue
11
Pages
1430-1436
ISSN
  • 0269-8811 (ISSN-L)
  • 1461-7285
OpenAlex
W2753967614
Cited by
67
References
77
Citations by year
2026: 6 · 2025: 7 · 2024: 6 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 13 · 2019: 10 · 2018: 4 · 2017: 1
FWCI
1.16
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • SHURA (Sheffield Hallam University Research Archive) (Sheffield Hallam University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
antipsychotic-induced weight gain, schizophrenia, metabolic disorders, cardiovascular risk, 5-HT2C receptor, dopamine D2 receptor, histamine H1 receptor, M3 muscarinic receptor, glucose regulation, aripiprazole, pharmacogenetics, drug response variability, predictive genetic testing, personalized medicine
MeSH terms
Animals, Humans, Pharmacogenetics, Psychotic Disorders, Risk Factors, Schizophrenia, Antipsychotic Agents, Weight Gain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment. https://app.cochat.ai/papers/10.1177/0269881117722987
The paper
Reynolds, G. P., & McGowan, O. O. (2017). Mechanisms underlying metabolic disturbances associated with psychosis and antipsychotic drug treatment. Journal of Psychopharmacology. https://doi.org/10.1177/0269881117722987

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.